Catalog #SIM0056
InVivoSIM anti-human BCMA (Belantamab Biosimilar)
Clone
Belantamab
Reactivities
Human, Monkey
Applications
in vivo functional assays
in vitro functional assays
Flow cytometry
Immunoprecipitation
Western blot
ELISA
in vitro functional assays
Flow cytometry
Immunoprecipitation
Western blot
ELISA
Isotype
Human IgG1, κ
Product Description
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Belantamab, making it ideal for research use. Belantamab is a humanized IgG1 monoclonal antibody that reacts with B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17). BCMA is a single-pass type III membrane glycoprotein, and it is selectively expressed by mature or differentiated plasma B-cells in normal lymphoid tissues (e.g., bone marrow, spleen, lymph nodes, and tonsils). BCMA is not expressed on naive B cells, T cells, monocytes/macrophages, neutrophils, and other normal tissues. BCMA is expressed uniformly and in high abundance in multiple myeloma tissues, and its low-to-moderate levels of expression are reported in several other hematologic malignancies also (e.g., chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, and non-Hodgkin/Hodgkin lymphomas). BCMA acts as a receptor for two distinct agonist ligands: B cell-activating factor [BAFF (also known as TNFSF13B or BLyS)] and a proliferation-inducing ligand (APRIL, also called TNFSF13). In comparison to BAFF/Blys, BCMA binds APRIL/TNFSF13 with higher affinity. BCMA plays a critical role in promoting B-cell survival and the regulation of humoral immunity. BCMA is also involved in the activation of NF-kappa-B and JNK-3 signaling pathways. In multiple myeloma, BCMA expression is directly related to the growth/proliferation of cancer cells, and serum levels of soluble BCMA (sBCMA) are suggested as a potential biomarker in multiple myeloma. In several experimental studies, an antibody-drug conjugate (ADC) consisting of belantamab conjugated to mafodotin has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and apoptosis in cancer cells.
Specifications
| Isotype | Human IgG1, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 (E356D/M358L) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | E356D/M358L |
| Immunogen | Human BCMA (CD269) |
| Reported Applications |
in vivo functional assays in vitro functional assays Flow cytometry Immunoprecipitation Western blot ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| RRID | AB_3696395 |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |